VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LQDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LQDALiquidia Corporation
$56.73$5.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LQDA logo

Liquidia Corporation

LQDA
NASDAQ · Metabolic & Cardiovascular Biotech
$56.73
At close - Nov 17, 4:00 PM EST - USD
Market Cap$5.04B
P/E-53.9x
52W High$93.61
Volume1.8M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Surge Overshadowed by Volatile Losses and Dilution Risk

Liquidia's revenue has scaled sharply from $3.1M in 2025Q1 to $225.3M in 2026Q3, yet this growth rests on a very low base and shifting generic distribution economics rather than a proven organic run rate.

GrowthAccelerating
ProfitabilityModerate
ValuationAttractive
TechnicalsNeutral
Explore valuation models
MARKET ACTION

LQDA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-303% Peers

P/E is 303% below peer median

03

Market leadership

RS 86 · Leader

High momentum (Outperforming 86% of market)

04

Trend Check

N/A

Trend data unavailable

Next CatalystEstimated earnings · Feb 10
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue climbed to $225.3M in 2026Q3 with gross margins holding near 93%, but operating margin swung from +49.8% in 2026Q2 to -117.0% in 2026Q3, indicating operating leverage has not yet proven durable.

Analyst Consensus+37.8% target
Buy(10 analysts)
7 Buy2 Hold1 Sell

The Bull Case

Upside Catalysts

Upcoming conference presentations

Liquidia will present four posters at the PHA 2026 International PH Conference, showcasing advancements in respiratory and vascular disease treatments.

Bullish Reddit thesis

A bullish case for Liquidia was discussed on wallstreetbets, highlighting potential upside in the stock.

Strong SEC filing history

MarketBeat provides access to Liquidia's complete SEC filings through 2026, indicating transparency and regulatory compliance.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LQDA+80.67%
S&P 500 (^GSPC)+7.21%
1-Year Return
LQDA+99.75%
S&P 500 (^GSPC)+10.03%
3-Year Return
LQDA+796.21%
S&P 500 (^GSPC)+63.40%
5-Year Return
LQDA+1122.63%
S&P 500 (^GSPC)+66.67%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-53.9x
Forward P/E
128.9x
EV/EBITDA
N/A
FCF YieldCash Flow
4.0%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-53.9x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
25.1x
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$16.09-71.6%
Base (Fair)$26.59-53.7%
Bull$28.31-50.1%
$16.09 Bear$26.59 Base$28.31 Bull
Current Market Price: $56.73
Trades at a 113.4% premium to Base DCF ($26.59)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$158M+1031.2% YoY
Net income FY25
-$69M+47.1% YoY
Free cash flow FY25
-$40M+59.3% YoY
Operating margin FY25
-32.5%+834.2 pts YoY
ROIC (FY25)-102.5%
Avg ROIC 5Y-231.3%
ROE (TTM)-116.6%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate4/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 10, 2026
-$2.64-375.0%
vs $0.96
$225M+5.2%
vs $214M
Q3 2026
Aug 12, 2026
$0.74+5.7%
vs $0.70
$172M+1.9%
vs $168M
Q2 2026
May 11, 2026
$0.52+52.9%
vs $0.34
$133M+11.2%
vs $119M
Q2 2026
Mar 5, 2026
$0.15+87.5%
vs $0.08
$92M+3.9%
vs $89M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·4d ago
Liquidia: Yutrepia's PAH Franchise Has Room To Grow

Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients with PAH, Liquidia Corporation can continue generating revenue. YUTREPIA is already generating cash. Paid PAH starts will show how much of the lost PH-ILD growth LQDA can replace.

Zacks Investment Research·Nov 11, 2026
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.

Zacks Investment Research·Nov 11, 2026
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook

Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.

Defense World·Nov 11, 2026
Liquidia (NASDAQ:LQDA) Stock Price Breaks Above Fifty Day Moving Average Following Weak Earnings

Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a 50 day moving average of $49.65 and traded as high as $51.69. Liquidia shares last traded at $51.40, with a volume of 2,846,811 shares. The

Filtered for Liquidia CorporationMore Headlines
04

Compare before deciding

Benchmark LQDA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Liquidia Corporation (LQDA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LQDA logoLQDALiquidia CorporationCurrent
$56.73$5.04B-53.921031.18%-15.15%-116.64%—
UTHR logoUTHRUnited Therapeutics Corporation
$584.10$24.79B21.5010.61%38.61%19.18%—
MNKD logoMNKDMannKind Corporation
$4.07$1.3B-17.4222.23%-18.1%——
INVA logoINVAInnoviva, Inc.
$18.30$1.35B6.8218.52%43.79%15.84%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.06$8.5B-24.77-100%—-29.41%—
INSM logoINSMInsmed Incorporated
$121.86$26.41B-44.0266.73%-39.85%-82.75%—

Compare LQDA vs Peers

Liquidia Corporation (LQDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs UTHR

Most directly comparable listed peer for LQDA.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare LQDA against a more recognizable public peer.

Peer Set

Compare Top 5

vs UTHR, MNKD, INVA, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LQDA SEC Filings & Documents

Liquidia Corporation (LQDA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 10, 2026·SEC

Material company update

Aug 12, 2026·SEC

Material company update

Jun 17, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 19, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 10, 2026·SEC

FY 2026

Aug 12, 2026·SEC

FY 2026

May 11, 2026·SEC

Get notified when LQDA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LQDA Frequently Asked Questions

Liquidia Corporation (LQDA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Liquidia Corporation's revenue?

Liquidia Corporation (LQDA) reported $621.9M in revenue over the trailing twelve months. Revenue was $158.3M in fiscal year 2025. That is 1098% more than the $13.2M of fiscal year 2016.

How fast is Liquidia Corporation growing?

Liquidia Corporation (LQDA) grew revenue by 798.4% over the trailing twelve months, compared with the twelve months before.

Is LQDA profitable?

No. Liquidia Corporation (LQDA) reported a net loss of $94.2M over the trailing twelve months.

Dividend & Returns
What is LQDA's return on equity?

Liquidia Corporation (LQDA) had a return on equity (ROE) of -116.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Liquidia Corporation's free cash flow?

Liquidia Corporation (LQDA) generated $201.0M in free cash flow over the trailing twelve months.

What if you invested $1,000 in LQDA back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →